CompanyGraph
Guangdong Taienkang Pharmaceutical Co., Ltd.
301263 · SZSE · China
tai-kang.com.cnFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.24B, above the global median of $1.15B
- FinancialsAltman Z-Score 8.22: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.41%
Annual Rate
CNY 0.08Paid semi-annual
Payout Ratio
285.7%High
Payback Period
78.7 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
8.37BCNY1.24B · vs all stocks (USD)
Trailing P/E
345.17xRevenue (TTM)
679.75MCNY100.96M · vs all stocks (USD)
Profit Margin
3.78%Beta
0.3000xvs all stocks
52-Week Change
-30.21%vs all stocks
Forward Annual Dividend Yield
0.41%vs all stocks
Market Capitalization
8.37BCNY1.24B · vs all stocks (USD)
Enterprise Value
10.14BCNY1.51B · vs all stocks (USD)
Trailing P/E
345.17xForward P/E
25.76xPEG Ratio
-20.71xPrice to Sales (TTM)
12.96xPrice to Book (MRQ)
6.20xEnterprise to Revenue
14.91xEnterprise to EBITDA
155.61xGross Margin
62.88%Profit Margin
3.78%Operating Margin
17.96%Return on Assets (TTM)
-0.03%Return on Equity (TTM)
0.39%Revenue (TTM)
679.75MCNY100.96M · vs all stocks (USD)
Revenue per Share (TTM)
1.42CNYUpdated Aug 20, 2026Quarterly Revenue Growth
2.60%Gross Profit (TTM)
362.62MCNY53.86M · vs all stocks (USD)
EBITDA (TTM)
77.39MCNY11.49M · vs all stocks (USD)
Net Income (TTM)
25.67MCNY3.81M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.40%Operating Cash Flow (TTM)
-15.50MCNY-2.30M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
8.21MCNY1.22M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0833CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
0.41%vs all stocks
Trailing Annual Dividend Rate
0.2417CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.19%vs all stocks
Payout Ratio
285.72%Minority Interest (Equity)
69.95MCNYFY2025 · Dec 31, 2025Revenue
674.90MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
310.07MCNYFY2025 · Dec 31, 2025Gross Profit
364.83MCNYFY2025 · Dec 31, 2025Operating Income
13.14MCNY1.95M · vs all stocks (USD)
Pre-tax Income
-8.17MCNYFY2025 · Dec 31, 2025Income Tax Expense
-20.92MCNYFY2025 · Dec 31, 2025Net Income
12.75MCNYFY2025 · Dec 31, 2025EBIT
4.46MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
77.39MCNYFY2025 · Dec 31, 2025Research & Development
77.68MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
146.20MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.23MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.63MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0583CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0583CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
490.85MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
490.85MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
12.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
15.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-48.72MCNYFY2025 · Dec 31, 2025Free Cash Flow
-156.98MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
579.06MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
12.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
13.45MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-51.98MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.92MCNYFY2025 · Dec 31, 2025Capital Expenditures
-108.26MCNYFY2025 · Dec 31, 2025Purchase of Investments
-280.00MCNYFY2025 · Dec 31, 2025Sale of Investments
363.87MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-24.39MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
480.58MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-363.67MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-93.58MCNYFY2025 · Dec 31, 2025Other Financing Charges
52.92MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
76.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
510.60MSharesUpdated Aug 20, 2026Float Shares
313.16MSharesUpdated Aug 20, 2026% Held by Insiders
49.73%vs all stocks
% Held by Institutions
4.03%vs all stocks
Total Cash (MRQ)
576.56MCNY85.63M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.13CNYUpdated Aug 20, 2026Total Debt (MRQ)
359.39MCNY53.38M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2034xCurrent Ratio (MRQ)
2.21xBook Value per Share (MRQ)
3.34CNYUpdated Aug 20, 2026Total Assets
2.42BCNY359.01M · vs all stocks (USD)
Total Current Assets
1.13BCNYFY2025 · Dec 31, 2025Total Liabilities
676.07MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.28BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
174.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
501.41MCNYFY2025 · Dec 31, 2025Cash
579.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
674.30KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
579.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
40.20MCNYFY2025 · Dec 31, 2025Accounts Receivable
321.06MCNYFY2025 · Dec 31, 2025Inventory
98.81MCNYFY2025 · Dec 31, 2025Accounts Payable
172.51MCNYFY2025 · Dec 31, 2025Short-term Debt
280.11MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.62MCNYFY2025 · Dec 31, 2025Long-term Debt
81.48MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
61.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
425.50MCNYFY2025 · Dec 31, 2025Retained Earnings
327.17MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.74BCNY258.60M · vs all stocks (USD)
Treasury Stock
39.00MCNYFY2025 · Dec 31, 202552-Week Low
17.52CNYUpdated Aug 20, 202652-Week High
32.50CNYUpdated Aug 20, 202652-Week Change
-30.21%vs all stocks
Beta
0.3000xvs all stocks
50-Day MA
20.03CNYUpdated Aug 20, 2026200-Day MA
23.04CNYUpdated Aug 20, 2026Avg 10-Day Volume
6.36MSharesUpdated Aug 20, 2026Avg 30-Day Volume
6.26MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0600CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 3,812,481.666Operating Cash Flow (USD, TTM): -2,302,228.273
High gross margins eroded by operating costsNotable
Gross Margin: 0.63Profit Margin: 0.04
Financial Health
Altman Z-Score 8.22: safe zoneNotable
Altman Z-Score: 8.22
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.24B, above the global median of $1.15BNotable
Market cap (USD): 1,243,043,460.729Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule